Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia

Completed · Phase 3

Conditions studied: Nocturia

In brief

The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.

Key facts

Study ID

NCT01259128

Run by

Serenity Pharmaceuticals, Inc.

People needed

32

Starts

2010-04-01

Expected to finish

2010-11-01

Last updated by the study team

2020-11-17

Who can join

Age: 75 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male \& female greater or equal to 75 years of age, history of nocturia

You may not qualify if…

• CHF, Diabetes, Diabetes Insipidus, Renal Insufficiency, Heptatic Insufficiency, Incontinence, Illness requiring steroid, current or past urologic maliganancy, nephrotic syndrome
• Unexplained pelvic masses
• Urinary bladder surgery or radiotherapy
• Sleep apnea

Where it is running

• Dr. Jolene Berg — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.